Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer

NCT01336049 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Cancer

Interventions

DRUG: Nimotuzumab

Sponsor

Peking University